Skip to main content

Advertisement

Log in

Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Breast cancer is the most common female cancer in Europe, but its incidence and mortality are rapidly changing across Europe. The early termination of the women’s health initiative (WHI) trial, after the detection of an increased breast cancer risk in hormone replacement therapy (HRT) users, was followed by strong declines of HRT use worldwide. We investigated whether the reduction of HRT sales affected breast cancer incidence in the Belgian province Limburg. All women registered in the Limburg Cancer Registry with a diagnosis of invasive breast cancer diagnosed between 1/1/1996 and 31/12/2005 were included in the study. Data on the use of HRT in the population were obtained from the vendors and the social security system. For age-standardization using the direct method, the European standard population was taken. In 2003 and 2004, the breast cancer incidence rate decreased significantly as compared to 2002 for women aged between 50 and 69 years. This sudden drop in the incidence intercepted a markedly increasing trend until 2002, but was followed again by an increase in 2005. Between 2002 and 2006, the sales of HRT (about 75% to women aged 50–69 years) were reduced by 41%. Breast cancer incidence was maximally related to HRT use in the previous year (R 2 = 77%). The decrease of breast cancer incidence in the Belgian province of Limburg may largely be related to the fall of HRT use following the early termination of the WHI trial. This suggests that HRT stimulates the growth of pre-existing, clinically latent tumours that may not otherwise become clinically apparent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW (2008) Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44(10):1345–1389. doi:10.1016/j.ejca.2007.12.015

    Article  PubMed  Google Scholar 

  2. Héry C, Ferlay J, Boniol M, Autier P (2008) Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 19(5):1009–1018. doi:10.1093/annonc/mdm593

    Article  PubMed  Google Scholar 

  3. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581–592. doi:10.1093/annonc/mdl498

    Article  CAS  PubMed  Google Scholar 

  4. Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2(3):133–140. doi:10.1016/S1470-2045(00)00254-0

    Article  CAS  PubMed  Google Scholar 

  5. World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington DC

    Google Scholar 

  6. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059. doi:10.1016/S0140-6736(97)08233-0

    Article  Google Scholar 

  7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333. doi:10.1001/jama.288.3.321

    Article  CAS  PubMed  Google Scholar 

  8. Majumdar SR, Almasi EA, Stafford RS (2004) Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA 292(16):1983–1988. doi:10.1001/jama.292.16.1983

    Article  CAS  PubMed  Google Scholar 

  9. Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427. doi:10.1016/S0140-6736(03)14065-2

    Article  CAS  PubMed  Google Scholar 

  10. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674. doi:10.1056/NEJMsr070105

    Article  CAS  PubMed  Google Scholar 

  11. Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K (2004) Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 48(1):39–49. doi:10.1016/j.maturitas.2003.08.006

    Article  CAS  PubMed  Google Scholar 

  12. Soerjomataram I, Coebergh JW, Louwman MW, Visser O, van Leeuwen FE (2007) Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? J Clin Oncol 25(31):5038–5039. doi:10.1200/JCO.2007.13.7281

    Article  PubMed  Google Scholar 

  13. National Institute for Statistics Bevolkingsdata (2008) http://ecodata.mineco.fgov.be/. Ministry of Economics, Vooruitgangsstraat 50, Brussel

  14. Lousbergh D, Cloes E, Op De Beeck L, Rummens JL, Vandenbrande J, Faes C, Bruckers L, Molenberghs G, Dhollander D, Kellen E, Hensen K, Lathouwers D, Meekers E, Buntinx F (2007) Ten years of cancer in the Belgian Province of Limburg: 1996–2005. LIKAR, Hasselt

    Google Scholar 

  15. IMS Health Belgium, Rue de Crayer 6, 1000 Brussels (2008) Drug sales in Belgium per three months

  16. Albertazzi P, Di Micco R, Zanardi E (1998) Tibolone: a review. Maturitas 30(3):295–305. doi:10.1016/S0378-5122(98)00059-0

    Article  CAS  PubMed  Google Scholar 

  17. dos Santos Silva I (1999) Cancer epidemiology: principles and methods. IARC, Lyon

  18. Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107(3):427–430. doi:10.1007/s10549-007-9566-z

    Article  CAS  PubMed  Google Scholar 

  19. Verkooijen HM, Koot VC, Fioretta G, van der Heiden M, Schipper ME, Rapiti E et al (2008) Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 107(3):389–395. doi:10.1007/s10549-007-9554-3

    Article  CAS  PubMed  Google Scholar 

  20. Van Duijnhoven FJ, van Gils CH, Bezemer ID, Peeters PH, van der Schouw YT, Grobbee DE (2006) Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. Maturitas 53(4):462–475. doi:10.1016/j.maturitas.2005.08.002

    Article  PubMed  Google Scholar 

  21. Zahl PH, Maehlen J (2007) A decline in breast-cancer incidence. N Engl J Med 357(5):510–511

    CAS  PubMed  Google Scholar 

  22. Botha JL, Bray F, Sankila R, Parkin DM (2003) Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 39(12):1718–1729

    Article  CAS  PubMed  Google Scholar 

  23. Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 9(3):R28. doi:10.1186/bcr1672

    Article  PubMed  Google Scholar 

  24. VRIND Statistisch Jaarrapporten Vlaamse regering (1998–2000) http://aps.vlaanderen.be/statistiek/publicaties/stat_Publicaties_vrind.htm

  25. Intermutualistisch Agentschap. Programma borstkankerscreening (2008) Periodes van 2002–2003 en 2004–2005. www.nic-ima.be

  26. Kumle M (2008) Declining breast cancer incidence and decreased HRT use. Lancet 372(9639):608–610. doi:10.1016/S0140-6736(08)61255-6

    Article  PubMed  Google Scholar 

  27. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288(7):872–881. doi:10.1001/jama.288.7.872

    Article  CAS  PubMed  Google Scholar 

  28. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA (2007) Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99(17):1335–1339. doi:10.1093/jnci/djm111

    Article  PubMed  Google Scholar 

  29. Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918. doi:10.1016/S1470-2045(06)70911-1

    Article  CAS  PubMed  Google Scholar 

  30. Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16(12):2773–2780. doi:10.1158/1055-9965.EPI-07-0546

    Article  PubMed  Google Scholar 

  31. Centers for Disease Control and Prevention (2007) Decline in breast cancer incidence—United States 1999–2003. MMWR 56:549–553

    Google Scholar 

  32. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE et al (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321. doi:10.1200/JCO.2003.05.151

    Article  CAS  PubMed  Google Scholar 

  33. Garcia-Closas M, Sherman ME, Brinton LA (2006) Clarifying breast cancer risks associated with menopausal hormone therapy. Lancet Oncol 7(11):885–886. doi:10.1016/S1470-2045(06)70915-9

    Article  PubMed  Google Scholar 

  34. Dietel M, Lewis MA, Shapiro S (2005) Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20(8):2052–2060. doi:10.1093/humrep/dei043

    Article  CAS  PubMed  Google Scholar 

  35. Prasad R, Boland GP, Cramer A, Anderson E, Knox WF, Bundred NJ (2003) Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer 98(12):2539–2546. doi:10.1002/cncr.11836

    Article  CAS  PubMed  Google Scholar 

  36. Early Breast Cancer Trialist’s Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0

    Article  Google Scholar 

Download references

Acknowledgments

This research project was financially supported by the Foundation against Cancer, Belgium. The Limburg Cancer Registry is funded by the Flemish Ministry of Health and the Province of Limburg.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Patrik Vankrunkelsven.

Appendix

Appendix

See Table 2.

Table 2 List of the preparations included in the analysis

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vankrunkelsven, P., Kellen, E., Lousbergh, D. et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 118, 425–432 (2009). https://doi.org/10.1007/s10549-009-0346-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0346-9

Keywords

Navigation